Strike Ends at Shasun API Plant but Share Price Takes Hit

Strike Ends at Shasun API Plant but Share Price Takes Hit
Operations have restarted at one of Shasun’s API facilities in India following a strike last month.

The strike – which was deemed ‘illegal’ by the firm when it began on June 15​ at the Puducherry, India API (active pharmaceutical ingredient) and finished formulation plant – led to the halting of production, including ibuprofen which is manufactured from the site, with operations recommencing only after 12 days.

In a regulatory filing​, the company said: “Shasun Pharmaceuticals Ltd has informed BSE [the Bombay Stock Exchange] that an amicable settlement has been reached with the workers at the Company's Pondicherry facility.

“The strike has been called off and operations resumed from yesterday night [June 27].”

The company has not revealed what the twelve days of striking may have cost though a 15-day strike over wage settlements at the same facility in May 2011 cost an estimated INR 50m ($853,000).

However, the company’s share prices reached a 52-week low on June 26 as the firm felt the full effect of the workers’ strike.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars